Piper Jaffray analyst Matt O'Brien views TransEnterix's (TRXC) announcement that the FDA had rejected the 510 submission for its SurgiBot robotic system as a incremental positive for Intuitive Surgical (ISRG). The delay may impact both the ongoing European launch and the upcoming domestic introduction of TransEnterix's more feature-rich ALF-X product, O'Brien tells investors in a research note. The analyst believes TransEnterix is the biggest near-term competitive threat to Intuitive. O'Brien keeps a Neutral rating on Intuitive Surgical due to valuation.